PT-141 for men has a real but limited clinical record. Small early trials found measurable erectile responses after intranasal or subcutaneous bremelanotide, including in men who said sildenafil did not work reliably for them. Those studies provide a signal worth discussing with a clinician. They do not provide phase 3 evidence, establish a standard treatment for male erectile dysfunction, or predict how one individual will respond.
PT-141 is another name for bremelanotide. Its central melanocortin pathway differs from the vascular pathway targeted by sildenafil and tadalafil. How PT-141 works covers that biology in detail, while PT-141 side effects covers the broader tolerability record.
What the PT-141 for men studies found
The clearest early evidence comes from three studies, each answering a slightly different question.
Intranasal PT-141 in men who responded to Viagra. In a randomized, double-blind 2004 study, Diamond and colleagues tested intranasal PT-141 in healthy men and men with mild-to-moderate erectile dysfunction who responded to Viagra. RigiScan measurements showed a statistically significant erectile response versus placebo at doses above 7 mg, with the first erection beginning at about 30 minutes (Diamond et al., International Journal of Impotence Research 2004). This was a short laboratory study of physiology, not a long-term test of successful intercourse or relationship satisfaction.
Subcutaneous PT-141 after an inadequate Viagra response. A second 2004 crossover study evaluated healthy men and a small group with erectile dysfunction who reported achieving an erection suitable for penetration no more than half the time while using Viagra. In that latter group, both studied subcutaneous doses produced significantly more erectile activity than placebo during visual sexual stimulation (Rosen et al., International Journal of Impotence Research 2004). This route is more relevant to injectable PT-141, but a small crossover experiment does not establish an individualized compounded protocol.
A larger intranasal trial in sildenafil nonresponders. A 2008 randomized study enrolled 342 men and reported a positive clinical result in 33.5% of the bremelanotide group versus 8.5% of the placebo group (Safarinejad and Hosseini, Journal of Urology 2008). There is an important qualification: the journal posted an expression of concern about that article in 2023. Its numbers can be reported, but they should not carry the conclusion by themselves.
What those results do and do not mean
The male studies support a biological and clinical signal. They do not show that PT-141 permanently corrects erectile dysfunction, raises testosterone, or works for every cause of an erection problem. The trials were short, used different routes and outcome measures, and mostly predate current standards for late-stage development. No published phase 3 efficacy trial in men had appeared as of August 2026.
The distinction between an erection measured in a clinic and a useful result at home matters. RigiScan can document rigidity and duration. It cannot settle whether desire, timing, comfort, partner dynamics, or an underlying medical condition is the main problem. That is why a clinician first needs to clarify whether the concern is desire, arousal, erection quality, or more than one of these.
PT-141 for men versus PDE5 inhibitors
PT-141 and PDE5 inhibitors approach erectile response from different directions. That makes PT-141 medically interesting when a PDE5 inhibitor has been inadequate, but it does not make the two interchangeable.
| Question | PT-141 (bremelanotide) | PDE5 inhibitors such as sildenafil |
|---|---|---|
| Primary pathway | Central melanocortin signaling involved in sexual response | Preserves cGMP signaling that supports blood flow in penile tissue |
| Male evidence | Small early trials; no published phase 3 male efficacy dataset as of August 2026 | Large development programs and labeled indications for male erectile dysfunction |
| What early studies measured | Rigidity, duration and some patient-reported outcomes | Erectile function and successful sexual attempts across broad populations |
| Clinical position | Off-label, individualized consideration | Usual first medication class considered for erectile dysfunction |
The trials do not justify combining the two without medical review. A 2005 crossover study of 19 men did examine low-dose intranasal PT-141 with sildenafil and found more erectile activity than sildenafil with placebo spray (Diamond et al., Urology 2005). That is a hypothesis-generating result, not a reader-directed combination protocol.
Kisspeptin is a different conversation again. It acts through the reproductive hormone axis and is studied for questions involving reproductive signaling and desire, rather than inheriting PT-141's erectile-response evidence. A clinician browsing mood and libido options may consider which question actually fits before comparing compounds.
Why the original male program stalled
The male program did not stop because one definitive trial proved bremelanotide ineffective. In 2007, the sponsors delayed planned phase 3 erectile-dysfunction studies after the FDA questioned the overall efficacy and clinical benefit shown to that point and identified blood-pressure increases as its greatest safety concern, according to the companies' contemporaneous filing preserved by the SEC.
The intranasal formulation also produced variable drug exposure. Later development moved to subcutaneous administration to make exposure more predictable. The FDA's multidiscipline review of bremelanotide describes that route change and the additional blood-pressure monitoring used in the subsequent program. The phase 3 registration program that followed enrolled premenopausal women with hypoactive sexual desire disorder, not men with erectile dysfunction.
This history explains the mismatch today: the molecule has male trial data, but the marketed label came from a different population, indication, route, and later-stage evidence package.
Approval status and the blood-pressure boundary
Vyleesi is FDA-approved; compounded PT-141 is not FDA-approved. The Vyleesi prescribing information limits the brand's indication to acquired, generalized hypoactive sexual desire disorder in premenopausal women and explicitly says it is not indicated in men or to enhance sexual performance.
The same label lists uncontrolled hypertension and known cardiovascular disease as contraindications. In its female trials, the labeled product produced temporary average peak increases of 6 mmHg systolic and 3 mmHg diastolic, usually returning to baseline within 12 hours. Those figures are not male efficacy data, but they explain why blood pressure and cardiovascular history belong in a prescribing review.
FDA review status is one input, not a marketing gate or a substitute for clinical judgment. A licensed provider may still prescribe a compounded formulation when they judge it appropriate; that decision belongs to the patient and the provider.
What a provider reviews for a man
A responsible review starts with the complaint itself. Erectile dysfunction can have vascular, neurologic, hormonal, medication-related, and psychological contributors. A provider may ask about blood-pressure control, cardiovascular disease, current medications, prior PDE5-inhibitor response, libido, morning erections, and relevant laboratory work rather than treating every concern as the same problem.
At Promise, a licensed provider reviews every request, and not everyone qualifies. The prescribed dose and timing are set by that clinician; PT-141 dosing decisions explains what shapes that choice without turning a published study dose into self-administration instructions.
Where PT-141 may fit
The most defensible place for PT-141 in men's care is an individualized discussion after the problem has been characterized and conventional options have been reviewed. Its early male data are stronger than an anecdote and weaker than a modern registration program. That middle ground is the honest answer: there is enough evidence to explain the clinical interest, but not enough to treat PT-141 as a proven replacement for sildenafil or as a universal answer to low desire.